XML 249 R99.htm IDEA: XBRL DOCUMENT
v3.25.2

Moderna Collaboration and License Agreement - Narrative (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 42 Months Ended
--- | --- | --- | --- | --- | ---
Feb. 28, 2025 item | Jun. 30, 2024 USD ($) | Jan. 31, 2022 USD ($) item product | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) item | Jun. 30, 2024 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Jun. 30, 2025 USD ($)
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  |  | $ 3,700 | $ 12,600 | $ 19,600 | $ 14,900 |
Collaboration revenues |  |  |  | $ 0 | $ 9,197 | 3,729 | $ 12,594 | 19,632 | $ 14,919 |
Option Right Collaboration Revenues |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  |  |  |  | 3,800 |  |
Collaboration and License Agreement | Research and Development Services |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Noncurrent portion of deferred revenue |  |  |  | $ 41,300 |  | 41,300 |  | 41,300 |  | $ 41,300
Moderna License Agreement | Research and Development Services |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  |  |  |  | 38,700 |  | 42,400
Moderna License Agreement | Option Right Collaboration Revenues |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  |  |  |  |  |  | $ 3,800
Moderna | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Maximum of research targets | item |  |  | 12 |  |  |  |  |  |  |
Number of oncology research targets | item | 12 |  |  |  |  |  |  |  |  |
Number of oncology research targets, nominated | item | 10 |  |  |  |  |  |  |  |  |
Number of research targets, replacement nominations | item | 4 |  |  |  |  |  |  |  |  |
Number of oncology research targets, ceased development | item | 2 |  |  |  |  |  |  |  |  |
Number of nominated autoimmune target | item | 2 |  |  |  |  |  |  |  |  |
Moderna | Collaboration and License Agreement | Research and Development Services |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Upfront non-refundable payment received |  |  | $ 45,000 |  |  | $ 45,000 |  | $ 45,000 |  |
Number of potential products to develop and commercialize | product |  |  | 12 |  |  |  |  |  |  |
Number of performance obligations | item |  |  |  |  |  | 2 |  |  |  |
Moderna | Collaboration and License Agreement | Research and Development Services | Minimum |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Amount receivable per product |  |  | $ 247,000 |  |  |  |  |  |  |
Moderna | Collaboration and License Agreement | Research and Development Services | Maximum |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Amount receivable per product |  |  | $ 253,000 |  |  |  |  |  |  |
Moderna | Moderna License Agreement |  |  |  |  |  |  |  |  |  |
Moderna Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  | $ 2,000 |  |  |  |  |  |  |  |

X
- Definition Amount receivable per product in development target designation, development, regulatory and commercial milestone payments. + References No definition available. + Details
Name: | carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum number of research targets. + References No definition available. + Details
Name: | carm_MaximumNumberOfResearchTargets
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Performance Obligations + References No definition available. + Details
Name: | carm_NumberOfPerformanceObligations
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of potential products to develop and commercialize + References No definition available. + Details
Name: | carm_NumberOfPotentialProductsToDevelopAndCommercialize
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Gross, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsGrossOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Research Targets Nominated, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsNominatedOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets Nominated, Replacements + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsNominatedReplacements
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Terminated, Autoimmune + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsTerminatedAutoimmune
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Research Targets, Terminated, Oncology + References No definition available. + Details
Name: | carm_NumberOfResearchTargetsTerminatedOncology
Namespace Prefix: | carm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront non-refundable payment received. + References No definition available. + Details
Name: | carm_UpfrontNonRefundablePaymentReceived
Namespace Prefix: | carm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |